MXCT MaxCyte, Inc.
MaxCyte, Inc. (MXCT) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.8% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MaxCyte, Inc.
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies.
Sector
Healthcare
Industry
Medical Instruments/Supply